U.S. Markets open in 6 hrs 15 mins
  • China Nepstar Chain Drugstore Ltd. :NPD-US: Earnings Analysis: Q1, 2016 By the Numbers : June 22, 2016
    Capital Cube11 months ago

    China Nepstar Chain Drugstore Ltd. :NPD-US: Earnings Analysis: Q1, 2016 By the Numbers : June 22, 2016

    Click here to see latest analysisChina Nepstar Chain Drugstore Ltd. reports financial results for the quarter ended March 31, 2016.We analyze the earnings along side the following peers of China Nepstar Chain Drugstore Ltd. – Rite Aid Corporation, PetMed Express, Inc. and CVS Health Corporation (RAD-US, PETS-US and CVS-US) that have also reported for this […] (Read more...) The post China Nepstar Chain Drugstore Ltd. :NPD-US: Earnings Analysis: Q1, 2016 By the Numbers : June 22, 2016 appeared first on CapitalCube.

  • China Nepstar Chain Drugstore Ltd. :NPD-US: Earnings Analysis: Q4, 2015 By the Numbers
    Capital Cubelast year

    China Nepstar Chain Drugstore Ltd. :NPD-US: Earnings Analysis: Q4, 2015 By the Numbers

    Click here to see latest analysisChina Nepstar Chain Drugstore Ltd. reports financial results for the quarter ended December 31, 2015.HighlightsSummary numbers: Revenues of USD 141.39 million, Net Earnings of USD 5.82 million.Gross margins widened from 42.45% to 44.74% compared to the same period last year, operating (EBITDA) margins now 7.06% from 6.28%.Earnings growth from operating […] (Read more...) The post China Nepstar Chain Drugstore Ltd. :NPD-US: Earnings Analysis: Q4, 2015 By the Numbers appeared first on CapitalCube.

  • Reuters2 years ago

    As China firms walk out on Wall St, spurned investors demand payback

    As dozens plan buyouts and a return home in search of higher valuations, companies that were once Wall Street's darlings for the first time face the wrath of minority shareholders. In deals collectively worth $40 billion, some 33 mainland China companies have unveiled plans this year to be taken private and delisted from the Unites States, according to Thomson Reuters data. "We want to put as much pressure as possible," said portfolio manager Lin Yang at FM Capital, a Britain-based hedge fund backed by the Libyan sovereign wealth fund that owns 1.4 percent of medical firm China Cord Blood Corp. FM Capital is urging a group of mainland China investors to raise a buyout offer, saying the shares are worth 2.5 times the proposed bid.